Bhatt, D L <br/><br/>
Abciximab reduces mortality in diabetics following percutaneous coronary intervention.  [electronic resource] 

 -  Journal of the American College of Cardiology  Mar 2000 
 - 922-8 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0735-1097 
<br/><br/><label>Standard No.: </label>10.1016/s0735-1097(99)00650-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abciximab<br/>Adult<br/>Aged<br/>Angina, Unstable--mortality<br/>Angioplasty, Balloon, Coronary<br/>Antibodies, Monoclonal--adverse effects<br/>Diabetic Angiopathies--mortality<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Immunoglobulin Fab Fragments--adverse effects<br/>Male<br/>Middle Aged<br/>Myocardial Infarction--mortality<br/>Platelet Aggregation Inhibitors--adverse effects<br/>Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors<br/>Randomized Controlled Trials as Topic<br/>Recurrence<br/>Risk Factors<br/>Stents<br/>Survival Rate